ABSTRACT
Diseases that involve the palmoplantar region are quite extensive. These diseases can only hold hands and feet, as well as other areas of simultaneous hold. In these regions, infectious disease, changes in reaction to infections, exzematized lesions, keratotic lesions, pustular lesions and erythematous lesions can be seen. Despite the limited area of skin involvement, the condition can have a significant negative effect on quality of life. This section will talk about the treatment of the most common diseases.
References
1Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59: e10-52.
2Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316: 325-337.
3Klauder JV. Erysipeloid as an occupational disease. JAMA 1938; 111: 1345.
4Venditti M, Gelfusa V, Tarasi A, et al. Antimicrobial susceptibilities of erysipelothrix rhusiopathiae. Antimicrob Agents Chemother 1990; 34: 2038-2040.
5Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166: 353-367.
6Bonifaz A, Badali H, de Hoog GS, et al. Tinea nigra by Hortaea werneckii, a report of 22 cases from Mexico. Stud Mycol 2008; 61: 77-82.
7Sayegh-Carreño R, Abramovits-Ackerman W, Girón GP. Therapy of tinea nigra plantaris. Int J Dermatol 1989; 28: 46-48.
8Kaptanoglu AF, Yuksel O, Ozyurt S. Plantar pitted keratolysis: a study from non-risk groups. Dermatol Reports 2012; 4: e4.
9De Luca JF, Adams BB, Yosipovitch G. Skin manifestations of athletes competing in the summer olympics: what a sports medicine physician should know. Sports Med 2012; 42: 399.
10Blaise G, Nikkels AF, Hermanns-Lê T, Nikkels-Tassoudji N, Piérard GE. Corynebacterium-associated skin infections. Int J Dermatol 2008; 47: 884.
11Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol 2017; 31: 1248-1253.
12Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236-240.
13Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ 2005; 331: 619-622.
14Scheinfeld NS. Is blistering distal dactylitis a variant of bullous impetigo? Clin Exp Dermatol 2007; 32: 314-316.
15Ferson MJ, Bell SM. Outbreak of Coxsackievirus A16 hand, foot, and mouth disease in a child day-care center. Am J Public Health 1991; 81: 1675-1676.
16Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. Br J Dermatol 2014; 171: 696-712.
17Choi MH, Seo SH, Kim IH, Son SW. Comparative study on the sustained efficacy of diphencyprone immunotherapy versus cryotherapy in viral warts. Pediatr Dermatol 2008; 25: 398-399.
18Thiers BH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 1997; 37: S69-71.
19Meyer A, Chatelus E, Wendling D, et al. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011; 63: 1274-1280.
20Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993; 128: 542-545.
21Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 2010; 62: 45-53.
22Kerob D, Assier-Bonnet H, Esnault-Gelly P, Blanc F, Saiag P. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol 1998; 134: 876-877.
23Sen P, Chua SH. A case of recurrent erythema multiforme and its therapeutic complications. Ann Acad Med Singap 2004; 33: 793-796.
24Veien NK. Acute and recurrent vesicular hand dermatitis. Dermatol Clin 2009; 27: 337-353.
25Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17: 240-250.
26Schnopp C, Remling R, Möhrenschlager M, Weigl L, Ring J, Abeck D. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46: 73-77.
27Mollerup A, Johansen JD, Thing LF. Knowledge, attitudes and behaviour in everyday life with chronic hand eczema: a qualitative study. Br J Dermatol 2013; 169: 1056-1065.
28Kampf G, Löffler H. Prevention of irritant contact dermatitis among health care workers by using evidence-based hand hygiene practices: a review. Ind Health 2007; 45: 645-652.
29Lodén M, Wirén K, Smerud K, et al. Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study. Acta Derm Venereol 2010; 90: 602-606.
30Draelos ZD. New treatments for restoring impaired epidermal barrier permeability: skin barrier repair creams. Clin Dermatol 2012; 30: 345-348.
31Katsarou A, Makris M, Papagiannaki K, Lagogianni E, Tagka A, Kalogeromitros D. Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol 2012; 22: 192-196.
32Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol 2010; 24 Suppl 3: 1-20.
33Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23: 10-14.
34Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis 2008; 58: 330-334.
35Koo JY, Ng TC. Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications. Clin Dermatol 2002; 20: 582-594.
36Selles RR, McGuire JF, Small BJ, Storch EA. A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder. Gen Hosp Psychiatry 2016; 41: 29-37.
37Gupta MA, Gupta AK. Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis 2000; 66: 143-146.
38Maverakis E, Fung MA, Lynch PJ, et al. Acrodermatitis enteropathica and an overview of zinc metabolism. J Am Acad Dermatol 2007; 56: 116-124.
39Neldner KH, Hambidge KM. Zinc therapy of acrodermatitis enteropathica. N Engl J Med 1975; 292: 879-882.
40Arosi I, Hiner G, Rajbhandari S. Pathogenesis and treatment of callus in the diabetic foot. Curr Diabetes Rev 2016; 12: 179-183.
41Freeman DB. Corns and calluses resulting from mechanical hyperkeratosis. Am Fam Physician 2002; 65: 2277-2280.
42Patel S, Zirwas M, English JC. Acquired palmoplantar keratoderma. Am J Clin Dermatol 2007; 8: 1-11.
43Braun-Falco M. Hereditary palmoplantar keratodermas. J Dtsch Dermatol Ges 2009; 7: 971-984.
44Kalia S, Adams SP. Dermacase. Juvenile plantar dermatosis. Can Fam Physician 2005; 51: 1203-1213.
45Gibbs NF. Juvenile plantar dermatosis. Can sweat cause foot rash and peeling? Postgrad Med 2004; 115: 73-75.
46Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-738.
47Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 2014; 28 Suppl 5: 13-16.
48Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119: 755-759.
49Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol 2011; 50: 1195-1211.
50Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 2014; 53: e464-466.
51Mancini AJ, Frieden IJ, Paller AS. Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. Pediatr Dermatol 1998; 15: 337-341.
52Van Praag MC, Van Rooij RW, Folkers E, Spritzer R, Menke HE, Oranje AP. Diagnosis and treatment of pustular disorders in the neonate. Pediatr Dermatol 1997; 14: 131-143.
53Kahn G, Rywlin AM. Acropustulosis of infancy. Arch Dermatol 1979; 115: 831-833.
54Krishnan SG, Yesudian DP, Jayaraman M, Janaki VR, Raj BJ. Erythromelalgia responding to aspirin. Indian J Dermatol Venereol Leprol 1996; 62: 204-205.
55Poterucha TJ, Weiss WT, Warndahl RA, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol 2013; 12: 308-310.
56Davis MD, Morr CS, Warndahl RA, Sandroni P. Topically applied midodrine, 0.2%, an α1-agonist, for the treatment of erythromelalgia. JAMA Dermatol 2015; 151: 1025-1026.
57Gales A, Chaaban B, Husson H, et al. Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations. Rev Neurol (Paris) 2016; 172: 399-400.
58Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med 2002; 4: 207-222.
59Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012; 23: 2103-2108.
60McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 2015; 26: 2017-2026.
61Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011; 9: 13-23.
62Garg K, Singh D, Mishra D. Peeling skin syndrome: Current status. Dermatol Online J 2010; 16: 10.
